RIGL Q2 2021 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RIGLRigel Pharmaceuticals, Inc.

$517M

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$26M+63.9% YoY

Gross Profit

$26M99.5% margin

Operating Income

-$13M-49.7% margin

Net Income

-$14M-52.6% margin

EPS (Diluted)

$-0.80

QoQ Revenue Growth

-67.6%

Cash Flow

Operating Cash Flow

$55M

Free Cash Flow

$55M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$202M

Total Liabilities

$133M

Stockholders' Equity

$68M

Cash & Equivalents

$85M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$26M	$16M	+63.9%
Gross Profit	$26M	$16M	+66.0%
Operating Income	-$13M	-$17M	+25.0%
Net Income	-$14M	-$18M	+21.4%

Revenue Segments

Gross Product

$22M47%

Product

$17M36%

Government Contract

$6M12%

Contract Revenues From Collaborations

$4M8%

License

$3M7%

Research And Development Services And Others

$408,0001%

Discounts And Allowances

-$5M-11%